Federal Register of Legislation - Australian Government

Primary content

PB 114 of 2019 Determinations/Health as amended, taking into account amendments up to National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 4) (PB 57 of 2020)
This determination outlines the manner in which the Commonwealth price for all or any pharmaceutical benefits is to be worked out for the purpose of payments to approved medical practitioners for the supply of pharmaceutical benefits and the conditions subject to which payments to medical practitioners and approved pharmacists will be made.
Administered by: Health
Registered 30 Jul 2020
Start Date 01 Jul 2020
End Date 31 Jul 2020

Commonwealth Coat of Arms of Australia

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)

made under subsection 98C(1) of the

National Health Act 1953

Compilation No. 4

Compilation date:                              1 July 2020

Includes amendments up to:            PB 57 of 2020

Registered:                                         30 July 2020

 

About this compilation

This compilation

This is a compilation of the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019) that shows the text of the law as amended and in force on 1 July 2020 (the compilation date).

The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.

Application, saving and transitional provisions for provisions and amendments

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Editorial changes

For more information about any editorial changes made in this compilation, see the endnotes.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.

Self‑repealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

  

  

  


Contents

Part 1—Preliminary                                                                                                                                        1

1............ Name............................................................................................................................. 1

3............ Authority....................................................................................................................... 1

5............ Simplified outline of this instrument.............................................................................. 1

6............ Definitions..................................................................................................................... 1

Part 2—Commonwealth price for pharmaceutical benefits supplied by approved medical practitioners                                                                                                                                                                  3

7............ Commonwealth price for pharmaceutical benefits supplied by approved medical practitioners                3

Part 3—Conditions on payments for pharmaceutical benefits supplied by approved pharmacists and approved medical practitioners                                                                                            4

8............ Scope of this Part.......................................................................................................... 4

9............ Condition on payment for supply of certain pharmaceutical items................................. 4

10.......... Payment for supply of certain pharmaceutical benefits in complete packs..................... 4

Schedule 1—Ready‑prepared pharmaceutical benefits that are mixtures of ready‑prepared ingredients                                                                           5

Schedule 2—Unstable or sterile ingredients used for extemporaneously‑prepared pharmaceutical benefits                                                                                    7

Schedule 3—Pharmaceutical benefits for which a dangerous drug fee applies               8

Schedule 4—Pharmaceutical benefits to be supplied as complete packs only    13

Schedule 5—Standard formula preparations                                                          26

1............ Standard formula preparations..................................................................................... 26

Endnotes                                                                                                                                                               28

Endnote 1—About the endnotes                                                                                                      28

Endnote 2—Abbreviation key                                                                                                          29

Endnote 3—Legislation history                                                                                                       30

Endnote 4—Amendment history                                                                                                     31

Endnote 5—Editorial changes                                                                                                          32

 


Part 1Preliminary

  

1  Name

             (1)  This instrument is the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019.

             (2)  This instrument may also be cited as PB 114 of 2019.

3  Authority

                   This instrument is made under subsection 98C(1) of the National Health Act 1953.

5  Simplified outline of this instrument

The Commonwealth price for pharmaceutical benefits supplied by an approved medical practitioner is worked out in the same way as the Commonwealth price for those benefits supplied by an approved pharmacist.

The Commonwealth will pay an approved medical practitioner or an approved pharmacist for supply of a pharmaceutical benefit only if certain conditions are met. They are as follows:

       (a)     if a determination under subsection 85(6) of the Act specifies a brand of the benefit, payment will be made only for supply of that brand of the benefit;

      (b)     if the benefit is specified in Schedule 4 to this instrument, payment will be made for supply of the benefit only if it is supplied in a complete pack.

Schedules 1, 2, 3 and 5 list pharmaceutical benefits and ingredients of pharmaceutical benefits for which particular rules apply for working out the Commonwealth price (whether the benefits are supplied by an approved medical practitioner or an approved pharmacist).

Schedule 4 lists pharmaceutical benefits that must be supplied in complete packs by an approved medical practitioner or an approved pharmacist for the practitioner or pharmacist to be paid by the Commonwealth for the supply.

6  Definitions

                   In this instrument:

Act means the National Health Act 1953.

approved medical practitioner has the meaning given by subsection 84(1) of the Act.

approved pharmacist has the meaning given by subsection 84(1) of the Act.

brand has the meaning given by subsection 84(1) of the Act.

extemporaneously‑prepared pharmaceutical benefit has the meaning given by subsection 6(1) of the Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020 (PB 66 of 2020).

listed drug has the meaning given by subsection 84(1) of the Act.

pharmaceutical benefit has the meaning given by subsection 84(1) of the Act.

pharmaceutical item has the meaning given by section 84AB of the Act.

Part 2Commonwealth price for pharmaceutical benefits supplied by approved medical practitioners

  

7  Commonwealth price for pharmaceutical benefits supplied by approved medical practitioners

             (1)  For the purposes of paragraph 98C(1)(a) of the Act, this section provides for the manner of ascertaining the Commonwealth price for a quantity, or number of units, of a pharmaceutical benefit supplied by an approved medical practitioner, for the purposes of a payment to the practitioner in respect of the supply.

             (2)  The Commonwealth price is to be ascertained in the same manner as the Commonwealth price for the supply would have been worked out under the Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020 (PB 66 of 2020) if the supply had been made by an approved pharmacist.

             (3)  Schedules 1, 2, 3 and 5 identify pharmaceutical benefits and ingredients in relation to which particular rules for ascertaining the Commonwealth price apply.

Note:          Those rules are in the Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020 (PB 66 of 2020), which is relevant because of subsection (2) of this section.

Part 3Conditions on payments for pharmaceutical benefits supplied by approved pharmacists and approved medical practitioners

  

8  Scope of this Part

                   For the purposes of paragraph 98C(1)(b) of the Act, this Part sets out the conditions subject to which payments will be made by the Commonwealth in respect of the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners.

9  Condition on payment for supply of certain pharmaceutical items

                   If a determination under subsection 85(6) of the Act is in force for a brand of a pharmaceutical item consisting of a drug or medicinal preparation, payments will be made by the Commonwealth in respect of the supply of the drug or preparation only if that brand is supplied.

10  Payment for supply of certain pharmaceutical benefits in complete packs

                   Payments will be made by the Commonwealth in respect of the supply of a listed drug in a form described in columns 1 and 2 of an item of Schedule 4 only if the quantity supplied is the quantity contained in a unit of the size described in column 2 of the item (even if the prescription for the supply is for supply of a lesser quantity).


Schedule 1Ready‑prepared pharmaceutical benefits that are mixtures of ready‑prepared ingredients

Note:       See subsection 7(3).

  

  

 

Ready‑prepared pharmaceutical benefits that are mixtures of ready‑prepared ingredients

Column 1
Listed drug with water purified ‑ BP

Column 2
Form

Amoxicillin

Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL

Amoxicillin

Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL

Amoxicillin

Powder for oral suspension 500 mg (as trihydrate) per 5 mL, 100 mL

Amoxicillin

Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL

Amoxicillin with clavulanic acid

Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL

Amoxicillin with clavulanic acid

Powder for oral suspension containing 400 mg amoxicillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL

Azithromycin

Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL

Cefaclor

Powder for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL

Cefaclor

Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL

Cefalexin

Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL

Cefalexin

Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL

Cefuroxime

Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL

Cefuroxime

Powder for oral suspension 125 mg (as axetil) per 5 mL, 100 mL

Clarithromycin

Powder for oral liquid 250 mg per 5 mL, 50 mL

Erythromycin

Powder for oral liquid 200 mg (as ethyl succinate) per 5 mL, 100 mL

Erythromycin

Powder for oral liquid 400 mg (as ethyl succinate) per 5 mL, 100 mL

Flucloxacillin

Powder for oral liquid 125 mg (as sodium monohydrate) per 5 mL, 100 mL

Flucloxacillin

Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL

Fluconazole

Powder for oral suspension 50 mg in 5 mL, 35 mL

Mycophenolic acid

Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL

Phenoxymethylpenicillin

Powder for oral liquid 125 mg (as potassium) per 5 mL, 100 mL

Phenoxymethylpenicillin

Powder for oral liquid 250 mg (as potassium) per 5 mL, 100 mL

Valganciclovir

Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL

Voriconazole

Powder for oral suspension 40 mg per mL, 70 mL

 

Schedule 2Unstable or sterile ingredients used for extemporaneously‑prepared pharmaceutical benefits

Note:       See subsection 7(3).

  

  

 

Unstable or sterile ingredients used for extemporaneously‑prepared pharmaceutical benefits

Ingredient

Water for injections—sterilised

 

Schedule 3Pharmaceutical benefits for which a dangerous drug fee applies

Note:       See subsection 7(3).

  

  

 

Pharmaceutical benefits for which a dangerous drug fee applies

Column 1
Listed drug

Column 2
Form

Alprazolam

Tablet 250 micrograms

Alprazolam

Tablet 500 micrograms

Alprazolam

Tablet 1 mg

Buprenorphine

Transdermal patch 5 mg

Buprenorphine

Transdermal patch 10 mg

Buprenorphine

Transdermal patch 15 mg

Buprenorphine

Transdermal patch 20 mg

Buprenorphine

Transdermal patch 25 mg

Buprenorphine

Transdermal patch 30 mg

Buprenorphine

Transdermal patch 40 mg

Codeine

Tablet containing codeine phosphate hemihydrate 30 mg

Dexamfetamine

Tablet containing dexamfetamine sulfate 5 mg

Fentanyl

Lozenge 200 micrograms (as citrate)

Fentanyl

Lozenge 400 micrograms (as citrate)

Fentanyl

Lozenge 600 micrograms (as citrate)

Fentanyl

Lozenge 800 micrograms (as citrate)

Fentanyl

Lozenge 1200 micrograms (as citrate)

Fentanyl

Lozenge 1600 micrograms (as citrate)

Fentanyl

Tablet (orally disintegrating) 100 micrograms (as citrate)

Fentanyl

Tablet (orally disintegrating) 200 micrograms (as citrate)

Fentanyl

Tablet (orally disintegrating) 400 micrograms (as citrate)

Fentanyl

Tablet (orally disintegrating) 600 micrograms (as citrate)

Fentanyl

Tablet (orally disintegrating) 800 micrograms (as citrate)

Fentanyl

Tablet (sublingual) 100 micrograms (as citrate)

Fentanyl

Tablet (sublingual) 200 micrograms (as citrate)

Fentanyl

Tablet (sublingual) 300 micrograms (as citrate)

Fentanyl

Tablet (sublingual) 400 micrograms (as citrate)

Fentanyl

Tablet (sublingual) 600 micrograms (as citrate)

Fentanyl

Tablet (sublingual) 800 micrograms (as citrate)

Fentanyl

Transdermal patch 1.28 mg

Fentanyl

Transdermal patch 2.063 mg

Fentanyl

Transdermal patch 2.1 mg

Fentanyl

Transdermal patch 2.55 mg

Fentanyl

Transdermal patch 4.125 mg

Fentanyl

Transdermal patch 4.2 mg

Fentanyl

Transdermal patch 5.10 mg

Fentanyl

Transdermal patch 7.65 mg

Fentanyl

Transdermal patch 8.25 mg

Fentanyl

Transdermal patch 8.4 mg

Fentanyl

Transdermal patch 10.20 mg

Fentanyl

Transdermal patch 12.375 mg

Fentanyl

Transdermal patch 12.6 mg

Fentanyl

Transdermal patch 16.5 mg

Fentanyl

Transdermal patch 16.8 mg

Hydromorphone

Injection containing hydromorphone hydrochloride 2 mg in 1 mL

Hydromorphone

Injection containing hydromorphone hydrochloride 10 mg in 1 mL

Hydromorphone

Oral liquid containing hydromorphone hydrochloride 1 mg per mL, 200 mL

Hydromorphone

Tablet containing hydromorphone hydrochloride 2 mg

Hydromorphone

Tablet containing hydromorphone hydrochloride 4 mg

Hydromorphone

Tablet containing hydromorphone hydrochloride 8 mg

Hydromorphone

Tablet (modified release) containing hydromorphone hydrochloride 4 mg

Hydromorphone

Tablet (modified release) containing hydromorphone hydrochloride 8 mg

Hydromorphone

Tablet (modified release) containing hydromorphone hydrochloride 16 mg

Hydromorphone

Tablet (modified release) containing hydromorphone hydrochloride 32 mg

Hydromorphone

Tablet (modified release) containing hydromorphone hydrochloride 64 mg

Lisdexamfetamine

Capsule containing lisdexamfetamine dimesilate 20 mg

Lisdexamfetamine

Capsule containing lisdexamfetamine dimesilate 30 mg

Lisdexamfetamine

Capsule containing lisdexamfetamine dimesilate 40 mg

Lisdexamfetamine

Capsule containing lisdexamfetamine dimesilate 50 mg

Lisdexamfetamine

Capsule containing lisdexamfetamine dimesilate 60 mg

Lisdexamfetamine

Capsule containing lisdexamfetamine dimesilate 70 mg

Methadone

Injection containing methadone hydrochloride 10 mg in 1 mL

Methadone

Oral liquid containing methadone hydrochloride 25 mg per 5 mL, 200 mL

Methadone

Tablet containing methadone hydrochloride 10 mg

Methylphenidate

Capsule containing methylphenidate hydrochloride 10 mg (modified release)

Methylphenidate

Capsule containing methylphenidate hydrochloride 20 mg (modified release)

Methylphenidate

Capsule containing methylphenidate hydrochloride 30 mg (modified release)

Methylphenidate

Capsule containing methylphenidate hydrochloride 40 mg (modified release)

Methylphenidate

Tablet containing methylphenidate hydrochloride 10 mg

Methylphenidate

Tablet containing methylphenidate hydrochloride 18 mg (extended release)

Methylphenidate

Tablet containing methylphenidate hydrochloride 27 mg (extended release)

Methylphenidate

Tablet containing methylphenidate hydrochloride 36 mg (extended release)

Methylphenidate

Tablet containing methylphenidate hydrochloride 54 mg (extended release)

Morphine

Capsule containing morphine sulfate pentahydrate 10 mg (containing sustained release pellets)

Morphine

Capsule containing morphine sulfate pentahydrate 20 mg (containing sustained release pellets)

Morphine

Capsule containing morphine sulfate pentahydrate 50 mg (containing sustained release pellets)

Morphine

Capsule containing morphine sulfate pentahydrate 100 mg (containing sustained release pellets)

Morphine

Capsule containing morphine sulfate pentahydrate 30 mg (controlled release)

Morphine

Capsule containing morphine sulfate pentahydrate 60 mg (controlled release)

Morphine

Capsule containing morphine sulfate pentahydrate 90 mg (controlled release)

Morphine

Capsule containing morphine sulfate pentahydrate 120 mg (controlled release)

Morphine

Injection containing morphine hydrochloride trihydrate 10 mg in 1 mL

Morphine

Injection containing morphine hydrochloride trihydrate 20 mg in 1 mL

Morphine

Injection containing morphine hydrochloride trihydrate 50 mg in 5 mL

Morphine

Injection containing morphine hydrochloride trihydrate 100 mg in 5 mL

Morphine

Injection containing morphine sulfate pentahydrate 10 mg in 1 mL

Morphine

Injection containing morphine sulfate pentahydrate 15 mg in 1 mL

Morphine

Injection containing morphine sulfate pentahydrate 30 mg in 1 mL

Morphine

Oral solution containing morphine hydrochloride trihydrate 2 mg per mL, 200 mL

Morphine

Oral solution containing morphine hydrochloride trihydrate 5 mg per mL, 200 mL

Morphine

Oral solution containing morphine hydrochloride trihydrate 10 mg per mL, 200 mL

Morphine

Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 20 mg per sachet

Morphine

Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 30 mg per sachet

Morphine

Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 60 mg per sachet

Morphine

Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 100 mg per sachet

Morphine

Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 200 mg per sachet

Morphine

Tablet containing morphine sulfate pentahydrate 10 mg

Morphine

Tablet containing morphine sulfate pentahydrate 20 mg

Morphine

Tablet containing morphine sulfate pentahydrate 30 mg

Morphine

Tablet containing morphine sulfate pentahydrate 5 mg (controlled release)

Morphine

Tablet containing morphine sulfate pentahydrate 10 mg (controlled release)

Morphine

Tablet containing morphine sulfate pentahydrate 15 mg (controlled release)

Morphine

Tablet containing morphine sulfate pentahydrate 30 mg (controlled release)

Morphine

Tablet containing morphine sulfate pentahydrate 60 mg (controlled release)

Morphine

Tablet containing morphine sulfate pentahydrate 100 mg (controlled release)

Morphine

Tablet containing morphine sulfate pentahydrate 200 mg (controlled release)

Oxycodone

Capsule containing oxycodone hydrochloride 5 mg

Oxycodone

Capsule containing oxycodone hydrochloride 10 mg

Oxycodone

Capsule containing oxycodone hydrochloride 20 mg

Oxycodone

Oral solution containing oxycodone hydrochloride 1 mg per mL, 250 mL

Oxycodone

Suppository 30 mg (as pectinate)

Oxycodone

Tablet containing oxycodone hydrochloride 5 mg

Oxycodone

Tablet containing oxycodone hydrochloride 10 mg (controlled release)

Oxycodone

Tablet containing oxycodone hydrochloride 15 mg (controlled release)

Oxycodone

Tablet containing oxycodone hydrochloride 20 mg (controlled release)

Oxycodone

Tablet containing oxycodone hydrochloride 30 mg (controlled release)

Oxycodone

Tablet containing oxycodone hydrochloride 40 mg (controlled release)

Oxycodone

Tablet containing oxycodone hydrochloride 80 mg (controlled release)

Oxycodone with naloxone

Tablet (controlled release) containing oxycodone hydrochloride 2.5 mg with naloxone hydrochloride 1.25 mg

Oxycodone with naloxone

Tablet (controlled release) containing oxycodone hydrochloride 5 mg with naloxone hydrochloride 2.5 mg

Oxycodone with naloxone

Tablet (controlled release) containing oxycodone hydrochloride 10 mg with naloxone hydrochloride 5 mg

Oxycodone with naloxone

Tablet (controlled release) containing oxycodone hydrochloride 15 mg with naloxone hydrochloride 7.5 mg

Oxycodone with naloxone

Tablet (controlled release) containing oxycodone hydrochloride 20 mg with naloxone hydrochloride 10 mg

Oxycodone with naloxone

Tablet (controlled release) containing oxycodone hydrochloride 30 mg with naloxone hydrochloride 15 mg

Oxycodone with naloxone

Tablet (controlled release) containing oxycodone hydrochloride 40 mg with naloxone hydrochloride 20 mg

Oxycodone with naloxone

Tablet (controlled release) containing oxycodone hydrochloride 60 mg with naloxone hydrochloride 30 mg

Oxycodone with naloxone

Tablet (controlled release) containing oxycodone hydrochloride 80 mg with naloxone hydrochloride 40 mg

Tapentadol

Tablet (modified release) 50 mg (as hydrochloride)

Tapentadol

Tablet (modified release) 100 mg (as hydrochloride)

Tapentadol

Tablet (modified release) 150 mg (as hydrochloride)

Tapentadol

Tablet (modified release) 200 mg (as hydrochloride)

Tapentadol

Tablet (modified release) 250 mg (as hydrochloride)

Schedule 4Pharmaceutical benefits to be supplied as complete packs only

Note:       See section 10.

  

  

 

Pharmaceutical benefits to be supplied as complete packs only

Column 1
Listed drug

Column 2
Form

Aciclovir

Eye ointment 30 mg per g, 4.5 g (Acivision)

Aclidinium

Powder for oral inhalation in breath actuated device 322 micrograms (as bromide) per dose, 60 doses

Aclidinium with formoterol

Powder for oral inhalation in breath actuated device containing aclidinium 340 micrograms (as bromide) with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses

Adapalene with benzoyl peroxide

Gel 1 mg‑25 mg per g, 30 g

Alendronic acid with colecalciferol and calcium

Pack containing 4 tablets containing alendronic acid 70 mg (as alendronate sodium) with 140 micrograms colecalciferol and 48 tablets calcium 500 mg (as carbonate)

Amoxicillin

Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL

Amoxicillin

Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL

Amoxicillin

Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL

Amoxicillin

Powder for oral suspension 500 mg (as trihydrate) per 5 mL, 100 mL

Amoxicillin with clavulanic acid

Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL

Amoxicillin with clavulanic acid

Powder for oral suspension containing 400 mg amoxicillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL

Apraclonidine

Eye drops 5 mg (as hydrochloride) per mL, 10 mL

Atenolol

Oral solution 50 mg in 10 mL, 300 mL

Atovaquone

Oral suspension 750 mg per 5 mL, 210 mL

Atropine

Eye drops containing atropine sulfate monohydrate 10 mg per mL, 15 mL

Azithromycin

Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL

Beclometasone

Pressurised inhalation containing beclometasone dipropionate 50 micrograms per dose, 200 doses (CFC‑free formulation)

Beclometasone

Pressurised inhalation containing beclometasone dipropionate 100 micrograms per dose, 200 doses (CFC‑free formulation)

Beclometasone

Pressurised inhalation in breath actuated device containing beclometasone dipropionate 50 micrograms per dose, 200 doses (CFC‑free formulation)

Beclometasone

Pressurised inhalation in breath actuated device containing beclometasone dipropionate 100 micrograms per dose, 200 doses (CFC‑free formulation)

Benzydamine

Mouth and throat rinse containing benzydamine hydrochloride 22.5 mg per 15 mL, 500 mL

Betaine

Oral powder 180 g

Betaxolol

Eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL

Bimatoprost

Eye drops 300 micrograms per mL, 3 mL

Bimatoprost

Eye drops 300 micrograms per mL, single dose units 0.4 mL, 30

Bimatoprost with timolol

Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, 3 mL

Bimatoprost with timolol

Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, single dose units 0.4 mL, 30

Bisacodyl

Enemas 10 mg in 5 mL, 25

Brigatinib

Pack containing 7 tablets 90 mg and 21 tablets 180 mg

Brimonidine

Eye drops containing brimonidine tartrate 1.5 mg per mL, 5 mL

Brimonidine

Eye drops containing brimonidine tartrate 2 mg per mL, 5 mL

Brimonidine with timolol

Eye drops containing brimonidine tartrate 2 mg with timolol 5 mg (as maleate) per mL, 5 mL

Brinzolamide

Eye drops 10 mg per mL, 5 mL

Brinzolamide with brimonidine

Eye drops 10 mg brinzolamide with 2 mg brimonidine tartrate per mL, 5 mL

Brinzolamide with timolol

Eye drops 10 mg brinzolamide with timolol 5 mg (as maleate) per mL, 5 mL

Budesonide

Nebuliser suspension 500 micrograms in 2 mL single dose units, 30

Budesonide

Nebuliser suspension 1 mg in 2 mL single dose units, 30

Budesonide

Powder for oral inhalation in breath actuated device 100 micrograms per dose, 200 doses

Budesonide

Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses

Budesonide

Powder for oral inhalation in breath actuated device 400 micrograms per dose, 200 doses

Budesonide with formoterol

Powder for oral inhalation in breath actuated device containing budesonide 100 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses

Budesonide with formoterol

Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses

Budesonide with formoterol

Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses, 2

Budesonide with formoterol

Pressurised inhalation containing budesonide 100 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses

Buprenorphine

Injection (modified release) 100 mg in 0.5 mL pre‑filled syringe

Buprenorphine

Injection (modified release) 300 mg in 1.5 mL pre‑filled syringe

Calcipotriol with betamethasone

Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g

Calcipotriol with betamethasone

Gel containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g

Calcipotriol with betamethasone

Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g

Captopril

Oral solution 5 mg per mL, 95 mL

Carbamazepine

Oral suspension 100 mg per 5 mL, 300 mL

Carbomer

Eye gel 2 mg per g, 10 g

Carmellose

Eye drops containing carmellose sodium 5 mg per mL, 10 mL

Carmellose

Eye drops containing carmellose sodium 5 mg per mL, 15 mL

Carmellose

Eye drops containing carmellose sodium 10 mg per mL, 15 mL

Carmellose with glycerin

Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL

Carmustine

Implants 7.7 mg, 8

Cefaclor

Powder for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL

Cefaclor

Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL

Cefalexin

Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL

Cefalexin

Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL

Cefuroxime

Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL

Cefuroxime

Powder for oral suspension 125 mg (as axetil) per 5 mL, 100 mL

Chloramphenicol

Eye drops 5 mg per mL, 10 mL

Chlorpromazine

Oral solution containing chlorpromazine hydrochloride 25 mg per 5 mL, 100 mL

Ciclesonide

Pressurised inhalation 80 micrograms per dose, 120 doses (CFC‑free formulation)

Ciclesonide

Pressurised inhalation 160 micrograms per dose, 120 doses (CFC‑free formulation)

Ciprofloxacin

Ear drops 3 mg (as hydrochloride) per mL, 5 mL

Citrulline

Tablet 1 g, 300 (Citrulline Easy)

Clarithromycin

Powder for oral liquid 250 mg per 5 mL, 50 mL

Clobetasol

Shampoo containing clobetasol propionate 500 micrograms per mL, 125 mL

Clonazepam

Oral liquid 2.5 mg per mL, 10 mL

Clozapine

Oral liquid 50 mg per mL, 100 mL

Cromoglycic acid

Pressurised inhalation containing sodium cromoglycate 1 mg per dose, 200 doses (CFC‑free formulation)

Cromoglycic acid

Pressurised inhalation containing sodium cromoglycate 5 mg per dose, 112 doses (CFC‑free formulation)

Degarelix

Powder for injection 120 mg (as acetate), 2, injection set

Desmopressin

Nasal spray (pump pack) containing desmopressin acetate 10 micrograms per actuation, 60 actuations, 6 mL

Dexamethasone

Eye drops 1 mg per mL, 5 mL

Dexamethasone

Intravitreal injection 700 micrograms

Dexamethasone with framycetin and gramicidin

Ear drops containing dexamethasone 500 micrograms (as sodium metasulfobenzoate), framycetin sulfate 5 mg and gramicidin 50 micrograms per mL, 8 mL

Diazepam

Oral liquid 1 mg in 1 mL, 100 mL

Dorzolamide

Eye drops 20 mg (as hydrochloride) per mL, 5 mL

Dorzolamide with timolol

Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL

Electrolyte replacement, oral

Oral rehydration salts containing glucose monohydrate 3.56 g, sodium chloride 470 mg, potassium chloride 300 mg and sodium acid citrate 530 mg per sachet, 10

Erythromycin

Powder for oral liquid 200 mg (as ethyl succinate) per 5 mL, 100 mL

Erythromycin

Powder for oral liquid 400 mg (as ethyl succinate) per 5 mL, 100 mL

Escitalopram

Oral solution 20 mg (as oxalate) per mL, 15 mL

Esomeprazole and clarithromycin and amoxicillin

Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate)

Esomeprazole and clarithromycin and amoxicillin

Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium trihydrate), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate)

Estradiol

Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28

Estradiol

Transdermal patches 390 micrograms, 8

Estradiol

Transdermal patches 585 micrograms, 8

Estradiol

Transdermal patches 780 micrograms, 8

Estradiol

Transdermal patches 1.17 mg, 8

Estradiol

Transdermal patches 1.56 mg, 8

Estradiol

Transdermal patches 2 mg, 4

Estradiol

Transdermal patches 3.8 mg, 4

Estradiol

Transdermal patches 5.7 mg, 4

Estradiol

Transdermal patches 7.6 mg, 4

Estradiol

Transdermal patches 750 micrograms (as hemihydrate), 8

Estradiol

Transdermal patches 1.5 mg (as hemihydrate), 8

Estradiol

Transdermal patches 3 mg (as hemihydrate), 8

Estradiol and estradiol with dydrogesterone

Pack containing 14 tablets estradiol 1 mg and 14 tablets estradiol 1 mg with dydrogesterone 10 mg

Estradiol and estradiol with dydrogesterone

Pack containing 14 tablets estradiol 2 mg and 14 tablets estradiol 2 mg with dydrogesterone 10 mg

Estradiol and estradiol with norethisterone

Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate

Estradiol and estradiol with norethisterone

Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate

Estradiol with norethisterone

Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8

Estradiol with norethisterone

Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8

Estriol

Pessaries 500 micrograms, 15

Estriol

Vaginal cream 1 mg per g, 15 g

Ethosuximide

Oral solution 250 mg per 5 mL, 200 mL

Ezetimibe and rosuvastatin

Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium)

Ezetimibe and rosuvastatin

Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium)

Ezetimibe and rosuvastatin

Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium)

Ezetimibe and rosuvastatin

Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium)

Ferrous sulfate

Oral liquid containing 30 mg ferrous sulfate heptahydrate per mL, 250 mL

Flucloxacillin

Powder for oral liquid 125 mg (as sodium monohydrate) per 5 mL, 100 mL

Flucloxacillin

Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL

Fluorometholone

Eye drops 1 mg per mL, 5 mL

Fluorometholone

Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL

Fluticasone furoate

Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms per dose, 30 doses

Fluticasone furoate

Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms per dose, 30 doses

Fluticasone furoate with umeclidinium and vilanterol

Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses

Fluticasone furoate with vilanterol

Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses

Fluticasone furoate with vilanterol

Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses

Fluticasone propionate

Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms per dose, 60 doses

Fluticasone propionate

Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms per dose, 60 doses

Fluticasone propionate

Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms per dose, 60 doses

Fluticasone propionate

Pressurised inhalation containing fluticasone propionate 50 micrograms per dose, 120 doses (CFC‑free formulation)

Fluticasone propionate

Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC‑free formulation)

Fluticasone propionate

Pressurised inhalation containing fluticasone propionate 250 micrograms per dose, 120 doses (CFC‑free formulation)

Fluticasone propionate with formoterol

Pressurised inhalation containing fluticasone propionate 50 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses

Fluticasone propionate with formoterol

Pressurised inhalation containing fluticasone propionate 125 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses

Fluticasone propionate with formoterol

Pressurised inhalation containing fluticasone propionate 250 micrograms with formoterol fumarate dihydrate 10 micrograms per dose, 120 doses

Fluticasone propionate with salmeterol

Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses

Fluticasone propionate with salmeterol

Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses

Fluticasone propionate with salmeterol

Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses

Fluticasone propionate with salmeterol

Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation)

Fluticasone propionate with salmeterol

Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation)

Fluticasone propionate with salmeterol

Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation)

Formoterol

Powder for oral inhalation in breath actuated device containing formoterol fumarate dihydrate 6 micrograms per dose, 60 doses

Formoterol

Powder for oral inhalation in breath actuated device containing formoterol fumarate dihydrate 12 micrograms per dose, 60 doses

Framycetin

Eye or ear drops containing framycetin sulfate 5 mg per mL, 8 mL

Furosemide

Oral solution 10 mg per mL, 30 mL

Gentamicin

Eye drops 3 mg (as sulfate) per mL, 5 mL

Glyceryl trinitrate

Sublingual spray (pump pack) 400 micrograms per dose, 200 doses

Glyceryl trinitrate

Tablets 600 micrograms, 100

Goserelin and bicalutamide

Pack containing 1 subcutaneous implant containing goserelin 3.6 mg (as acetate) in pre‑filled injection syringe and 28 tablets bicalutamide 50 mg

Goserelin and bicalutamide

Pack containing 1 subcutaneous implant containing goserelin 10.8 mg (as acetate) in pre‑filled injection syringe and 28 tablets bicalutamide 50 mg

Goserelin and bicalutamide

Pack containing 1 subcutaneous implant containing goserelin 10.8 mg (as acetate) in pre‑filled injection syringe and 84 tablets bicalutamide 50 mg

Haloperidol

Oral solution 2 mg per mL, 100 mL

Hyaluronic acid

Eye drops containing sodium hyaluronate 1 mg per mL, 10 mL

Hyaluronic acid

Eye drops containing sodium hyaluronate 2 mg per mL, 10 mL

Hydrocortisone

Cream containing hydrocortisone acetate 10 mg per g, 50 g

Hydrocortisone

Eye ointment containing hydrocortisone acetate 10 mg per g, 5 g

Hydrocortisone

Ointment containing hydrocortisone acetate 10 mg per g, 50 g

Hypromellose

0.3% w/v eye drops, 10 mL (preservative free)

Hypromellose

Eye drops 3 mg per mL, 10 mL

Hypromellose

Eye drops 5 mg per mL, 15 mL

Hypromellose with carbomer 980

Ocular lubricating gel 3 mg‑2 mg per g, 10 g

Hypromellose with dextran

Eye drops containing 3 mg hypromellose 4500 with 1 mg dextran 70 per mL, 15 mL

Ketoconazole

Cream 20 mg per g, 30 g

Ketoconazole

Shampoo 10 mg per g, 100 mL

Ketoconazole

Shampoo 20 mg per g, 60 mL

Lacosamide

Oral solution 10 mg per mL, 200 mL

Latanoprost

Eye drops 50 micrograms per mL, 2.5 mL

Latanoprost with timolol

Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL

Leuprorelin and bicalutamide

Pack containing 1 syringe containing leuprorelin 7.5 mg (as acetate) and 28 tablets bicalutamide 50 mg

Leuprorelin and bicalutamide

Pack containing 1 syringe containing leuprorelin 22.5 mg (as acetate) and 28 tablets bicalutamide 50 mg

Leuprorelin and bicalutamide

Pack containing 1 syringe containing leuprorelin 22.5 mg (as acetate) and 84 tablets bicalutamide 50 mg

Levetiracetam

Oral solution 100 mg per mL, 300 mL

Lumacaftor with ivacaftor

Sachet containing granules, lumacaftor 100 mg and ivacaftor 125 mg

Lumacaftor with ivacaftor

Sachet containing granules, lumacaftor 150 mg and ivacaftor 188 mg

Macrogol 3350

Powder for oral solution 510 g

Macrogol 3350

Sachets containing powder for oral solution 13.125 g with electrolytes, 30

Mercaptopurine

Oral suspension containing mercaptopurine monohydrate 20 mg per mL, 100 mL

Metronidazole

Oral suspension containing metronidazole benzoate 320 mg per 5 mL, 100 mL

Metronidazole

Suppositories 500 mg, 10

Miconazole

Cream containing miconazole nitrate 20 mg per g, 30 g

Miconazole

Cream containing miconazole nitrate 20 mg per g, 70 g

Miconazole

Powder containing miconazole nitrate 20 mg per g, 30 g

Miconazole

Tincture 20 mg per mL, 30 mL

Mifepristone and misoprostol

Pack containing 1 tablet mifepristone 200 mg and 4 tablets misoprostol 200 micrograms

Mupirocin

Nasal ointment 20 mg (as calcium) per g, 3 g

Mupirocin

Nasal ointment 20 mg (as calcium) per g, 5 g

Mycophenolic acid

Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL

Nafarelin

Nasal spray (pump pack) 200 micrograms (as acetate) per dose, 60 doses

Naloxone

Nasal spray 1.8 mg (as hydrochloride dihydrate) in 0.1 mL single dose unit, 2

Naproxen

Oral suspension 125 mg per 5 mL, 474 mL

Nedocromil

Pressurised inhalation containing nedocromil sodium 2 mg per dose, 112 doses (CFC‑free formulation)

Netupitant with palonosetron

Capsule containing netupitant 300 mg with palonosetron 500 microgram (as hydrochloride)

Nicorandil

Tablets 10 mg, 60

Nicorandil

Tablets 20 mg, 60

Ondansetron

Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL

Oxybutynin

Transdermal patches 36 mg, 8

Paracetamol

Oral liquid 120 mg per 5 mL, 100 mL

Paracetamol

Oral liquid 240 mg per 5 mL, 200 mL

Paraffin

Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g

Peginterferon beta‑1a

Pack containing single use injection pens containing 63 micrograms in 0.5 mL and 94 micrograms in 0.5 mL

Permethrin

Cream 50 mg per g, 30 g

Phenytoin

Oral suspension 30 mg per 5 mL, 500 mL

Pilocarpine

Eye drops containing pilocarpine hydrochloride 10 mg per mL, 15 mL

Pilocarpine

Eye drops containing pilocarpine hydrochloride 20 mg per mL, 15 mL

Pilocarpine

Eye drops containing pilocarpine hydrochloride 40 mg per mL, 15 mL

Pimecrolimus

Cream 10 mg per g, 15 g

Polyethylene glycol 400 with propylene glycol

Eye drops 4 mg‑3 mg per mL, 15 mL

Polyvinyl alcohol

Eye drops 14 mg per mL, 15 mL

Prednisolone

Oral solution 5 mg (as sodium phosphate) per mL, 30 mL

Prednisolone with phenylephrine

Eye drops containing prednisolone acetate 10 mg with phenylephrine hydrochloride 1.2 mg per mL, 10 mL

Quinagolide

Pack containing 3 tablets quinagolide 25 micrograms (as hydrochloride) and 3 tablets quinagolide 50 micrograms (as hydrochloride)

Reteplase

Pack containing 2 vials powder for injection 10 units, 2 single use pre‑filled syringes with solvent, 2 reconstitution spikes and 2 needles

Rifampicin

Syrup 100 mg per 5 mL, 60 mL

Risedronic acid and calcium

Pack containing 4 tablets risedronate sodium 35 mg and 24 tablets calcium 500 mg (as carbonate)

Risperidone

Oral solution 1 mg per mL, 100 mL

Salbutamol

Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20

Salbutamol

Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30

Salbutamol

Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 20

Salbutamol

Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30

Salbutamol

Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC‑free formulation)

Salmeterol

Powder for oral inhalation in breath actuated device 50 micrograms (as xinafoate) per dose, 60 doses

Semaglutide

Solution for injection 2 mg in 1.5 mL pre‑filled pen

Semaglutide

Solution for injection 4 mg in 3 mL pre‑filled pen

Silver sulfadiazine

Cream 10 mg per g, 50 g

Sirolimus

Oral solution 1 mg per mL, 60 mL

Sterculia with Frangula bark

Granules 620 mg‑80 mg per g, 500 g

Tafluprost

Eye drops 15 micrograms per mL, single dose units 0.3 mL, 30

Testosterone

Transdermal cream 50 mg per mL, 50 mL

Testosterone

Transdermal gel 50 mg in 5 g sachet, 30

Testosterone

Transdermal gel (pump pack) 12.5 mg per 1.25 g dose, 60 doses, 2

Testosterone

Transdermal gel (pump pack) 23 mg per 1.15 g dose, 56 doses

Testosterone

Transdermal patches 12.2 mg, 60

Testosterone

Transdermal patches 24.3 mg, 30

Theophylline

Oral solution 133.3 mg per 25 mL, 500 mL

Timolol

Eye drops 5 mg (as maleate) per mL, 5 mL

Timolol

Eye drops (gellan gum solution) 5 mg (as maleate) per mL, 2.5 mL

Tiotropium

Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations)

Tiotropium with olodaterol

Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses

Tobramycin

Eye drops 3 mg per mL, 5 mL

Tobramycin

Eye ointment 3 mg per g, 3.5 g

Tramadol

Oral drops containing tramadol hydrochloride 100 mg per mL, 10 mL

Travoprost

Eye drops 40 micrograms per mL, 2.5 mL

Travoprost with timolol

Eye drops 40 micrograms travoprost with timolol 5 mg (as maleate) per mL, 2.5 mL

Triamcinolone with neomycin, gramicidin and nystatin

Ear drops containing triamcinolone acetonide 0.9 mg with neomycin 2.25 mg (as sulfate), gramicidin 225 micrograms and nystatin 90,000 units per mL, 7.5 mL

Triamcinolone with neomycin, gramicidin and nystatin

Ear ointment containing triamcinolone acetonide 1 mg with neomycin 2.5 mg (as sulfate), gramicidin 250 micrograms and nystatin 100,000 units per g, 5 g

Trimethoprim with sulfamethoxazole

Paediatric oral suspension 40 mg‑200 mg per 5 mL, 100 mL

Umeclidinium

Powder for oral inhalation in breath actuated device 62.5 micrograms (as bromide) per dose, 30 doses

Umeclidinium with vilanterol

Powder for oral inhalation in breath actuated device containing umeclidinium 62.5 micrograms (as bromide) with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses

Varenicline

Box containing 11 tablets 0.5 mg (as tartrate) and 14 tablets 1 mg (as tartrate) in the first pack and 28 tablets 1 mg (as tartrate) in the second pack

Venetoclax

Pack containing 14 tablets venetoclax 10 mg and 7 tablets venetoclax 50 mg and 7 tablets venetoclax 100 mg and 14 tablets venetoclax 100 mg

 


Schedule 5Standard formula preparations

Note:       See subsection 7(3).

  

  

1  Standard formula preparations

                   Each extemporaneously‑prepared pharmaceutical benefit described in an item of the following table is a standard formula preparation for the purposes of working out the Commonwealth price for supply of the pharmaceutical benefit, unless the benefit:

                     (a)  varies from what is described in the item because of:

                              (i)  addition of an ingredient; or

                             (ii)  omission of an ingredient; or

                            (iii)  variation of the dose; or

                     (b)  is a combination of benefits described in 2 or more items of the table.

 

Standard formula preparations

Column 1
Form of pharmaceutical benefit

Column 2
Standard formula preparation

Column 3
Pharmaceutical reference standard

Creams

Salicylic Acid and Sulfur Aqueous

APF

Dusting Powders

Zinc, Starch and Talc

APF 15 or BPC 1973

Ear Drops

Aluminium Acetate

APF

Ear Drops

Aluminium Acetate

BP

Ear Drops

Sodium Bicarbonate

APF or BP

Ear Drops

Spirit

APF

Inhalations

Benzoin and Menthol

APF

Inhalations

Menthol

APF

Inhalations

Menthol and Eucalyptus

BP 1980

Linctuses containing Codeine Phosphate

Codeine

APF

Lotions

Aluminium Acetate Aqueous

APF

Mixtures, Other

Gentian Alkaline

APF

Mixtures, Other

Kaolin

BPC 1968

Mixtures, Other

Kaolin and Opium

APF 14

Mixtures, Other

Magnesium Trisilicate

BPC 1968

Mixtures, Other

Magnesium Trisilicate and Belladonna

BPC 1968

Mouth Washes

Thymol Compound

APF 15

Ointments, Waxes

Benzoic Acid Compound

APF or BP

Ointments, Waxes

Boric Acid, Olive Oil and Zinc Oxide

QHF

Ointments, Waxes

Salicylic Acid

APF

Ointments, Waxes

Salicylic Acid (extemporaneous formula)

BP

Paints

Podophyllin Compound

APF 16 or BP

Paints

Salicylic Acid

APF

Pastes, Other

Zinc

APF or BP

Powders for Internal Use

Magnesium Trisilicate

BP

 


Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

Abbreviation key—Endnote 2

The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Editorial changes

The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

Misdescribed amendments

A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.

If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.

Endnote 2—Abbreviation key

 

ad = added or inserted

o = order(s)

am = amended

Ord = Ordinance

amdt = amendment

orig = original

c = clause(s)

par = paragraph(s)/subparagraph(s)

C[x] = Compilation No. x

    /sub‑subparagraph(s)

Ch = Chapter(s)

pres = present

def = definition(s)

prev = previous

Dict = Dictionary

(prev…) = previously

disallowed = disallowed by Parliament

Pt = Part(s)

Div = Division(s)

r = regulation(s)/rule(s)

ed = editorial change

reloc = relocated

exp = expires/expired or ceases/ceased to have

renum = renumbered

    effect

rep = repealed

F = Federal Register of Legislation

rs = repealed and substituted

gaz = gazette

s = section(s)/subsection(s)

LA = Legislation Act 2003

Sch = Schedule(s)

LIA = Legislative Instruments Act 2003

Sdiv = Subdivision(s)

(md) = misdescribed amendment can be given

SLI = Select Legislative Instrument

    effect

SR = Statutory Rules

(md not incorp) = misdescribed amendment

Sub‑Ch = Sub‑Chapter(s)

    cannot be given effect

SubPt = Subpart(s)

mod = modified/modification

underlining = whole or part not

No. = Number(s)

    commenced or to be commenced

 

Endnote 3—Legislation history

 

Name

Registration

Commencement

Application, saving and transitional provisions

PB 114 of 2019

 29 Jan 2020 (F2020L00059)

1 Feb 2020 (s 2(1) item 1)

 

PB 22 of 2020

31 Mar 2020 (F2020L00358)

1 Apr 2020 (s 2)

PB 35 of 2020

30 Apr 2020 (F2020L00536)

1 May 2020 (s 2)

PB 43 of 2020

29 May 2020 (F2020L00644)

1 June 2020 (s 2)

PB 57 of 2020

30 June 2020 (F2020L00853)

1 July 2020 (s 2)

 

Endnote 4—Amendment history

 

Provision affected

How affected

Part 1

 

s 2.............................................

rep LA s 48D

s 4.............................................

rep LA s 48C

s 6.............................................

am F2020L00853

 

ed C4

Part 2

 

s 7.............................................

am F2020L00853

 

ed C4

Schedule 4

 

Schedule 4................................

am F2020L00358; F2020L00536; F2020L00644; F2020L00853

Schedule 6

 

Schedule 6................................

rep LA s 48C

 

Endnote 5—Editorial changes

In preparing this compilation for registration, the following kinds of editorial change(s) were made under the Legislation Act 2003.

 

Section 6 (definition of extemporaneously‑prepared pharmaceutical benefit), subsection 7(2) and section 7 (note)

 

Kind of editorial change

 

Give effect to the misdescribed amendments as intended and changes to typeface

 

Details of editorial change

 

Schedule 1 items 1 to 3 of the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 4) (PB 57 of 2020) instruct to omit “Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2015 (PB 64 of 2015)” and substitute “Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020 (PB 66 of 2020)” in section 6 (definition of extemporaneously‑prepared pharmaceutical benefit), subsection 7(2) and section 7 (note).

 

Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2015 (PB 64 of 2015)” does not appear. However, “Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2015 (PB 64 of 2015)” does appear.

 

This compilation was editorially changed to omit “Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2015 (PB 64 of 2015)” and substitute “Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020 (PB 66 of 2020)” in section 6 (definition of extemporaneously‑prepared pharmaceutical benefit), subsection 7(2) and section 7 (note) to give effect to the misdescribed amendments as intended and change the typeface to bring it into line with legislative drafting practices.